Evidence-based guidelines for the diagnosis and treatment of Kawasaki disease in children in China (2023).
10.7499/j.issn.1008-8830.2309038
- Collective Name:Center for Diagnosis and Treatment of Kawasaki Disease/Children's Hospital of Shaanxi Provincial People's Hospital;National Children's Medical Center/Beijing Children's Hospital, Capital Medical University;Children's Hospital,Shanghai Jiao Tong University School of Medicine;National Regional Medical Center/Shengjing Hospital of China Medical University;National Clinical Key Specialty/Department of Intensive Care Medicine, Shanghai Children'sHospital;Hospital; General Pediatric Group of Pediatrician Branch of Chinese Medical Doctor Association;Expert Committee of Advanced Training for Pediatrician, China Maternal and Children's Health Association;;National Health Commission Key Laboratory for Tropical Disease Prevention and Control;Yan'an University Affiliated Hospital;Editorial Department of Chinese Journal of Contemporary Pediatrics
- Publication Type:Journal Article
- Keywords:
Child;
Clinical practice guideline;
Diagnosis, Treatment;
Kawasaki disease
- MeSH:
Child;
Humans;
Child, Preschool;
Mucocutaneous Lymph Node Syndrome/complications*;
Vasculitis/drug therapy*;
Heart;
Heart Diseases;
China;
Immunoglobulins, Intravenous/therapeutic use*
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(12):1198-1210
- CountryChina
- Language:Chinese
-
Abstract:
Kawasaki disease (KD) is an acute self-limiting vasculitis, and it is the most common cause of acquired heart disease in children under 5 years old. One of the improvement goals in pediatric quality control work for the year 2023, as announced by the National Health Commission, is to reduce the incidence of cardiac events and KD-related mortality in children with KD. In order to standardize the diagnosis, treatment, and long-term management practices of KD in China, and effectively prevent and reduce the incidence of coronary artery lesions and long-term adverse effects, the guideline working group followed the principles and methods outlined by the World Health Organization and referenced existing evidence and experiences to develop the "Evidence-based guidelines for the diagnosis and treatment of Kawasaki disease in children in China (2023)". The guidelines address the clinical questions regarding the classification and definition of KD, diagnosis of different types of KD, treatment during the acute phase of KD, application of echocardiography in identifying complications of KD, and management of KD combined with macrophage activation syndrome. Based on the best evidence and expert consensus, 20 recommendations were formulated, aiming to provide guidance and decision-making basis for healthcare professionals in the diagnosis and treatment of KD in children.
